Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.56 |
| ▸ | MAT2A | P31153 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5490769 | 1.00 | NFE2L2 (0.56) | NFE2L2MAT2AKCNH2KMT2AALDH1A1 | |
| SCHEMBL29107871 | 0.86 | MAOB (0.47) | NFE2L2MAT2AKCNH2KMT2AALDH1A1 | |
| SCHEMBL27655212 | 0.84 | CYP2A6 (0.52) | NFE2L2MAT2AKCNH2KMT2AALDH1A1 | |
| SCHEMBL9814638 | 0.82 | ALDH1A1 (0.53) | NFE2L2MAT2AKCNH2KMT2AALDH1A1 | |
| SCHEMBL18843992 | 0.80 | KCNH2 (0.47) | NFE2L2MAT2AKCNH2KMT2AALDH1A1 | |
| SCHEMBL17083049 | 0.80 | KCNH2 (0.51) | NFE2L2MAT2AKCNH2KMT2AALDH1A1 | |
| SCHEMBL5247979 | 0.78 | ALDH1A1 (0.48) | NFE2L2KMT2AALDH1A1MEN1TDP1 | |
| SCHEMBL8802813 | 0.77 | ALDH1A1 (0.54) | NFE2L2MAT2AKCNH2KMT2AALDH1A1 | |
| SCHEMBL8802839 | 0.77 | HSD17B3 (0.50) | MAT2AKCNH2KMT2AALDH1A1MEN1 | |
| SCHEMBL18589846 | 0.77 | KCNH2 (0.49) | NFE2L2MAT2AKCNH2KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9925153-B2 | Therapeutic agents for skin diseases and conditions | STC.UNM (US) | 2018-03-27 | — | — | US | disclosed |
| US-20160287531-A1 | THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS | STC.UNM | 2016-10-06 | — | — | US | disclosed |
| US-8980954-B2 | Substituted cis- and trans-stilbenes as therapeutic agents | STC.UNM (US) | 2015-03-17 | — | — | US | disclosed |
| US-20130178536-A1 | SUBSTITUTED CIS- AND TRANS-STILBENES AS THERAPEUTIC AGENTS | STC.UNM (US) | 2013-07-11 | — | — | US | disclosed |
| US-20070249647-A1 | Substituted CIS- and trans-stilbenes as therapeutic agents | REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160287531-A1 | THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS | CUTA, TSLP, ELANE | NFE2L2 696/4885MAT2A 3323/4885KCNH2 4553/4885 |
| US-20070249647-A1 | Substituted CIS- and trans-stilbenes as therapeutic agents | TGFB1, VHL, TMSB10 | NFE2L2 68/4885MAT2A 1702/4885KCNH2 4757/4885 |
| US-20130178536-A1 | SUBSTITUTED CIS- AND TRANS-STILBENES AS THERAPEUTIC AGENTS | PSEN1, TERT, PSEN2 | NFE2L2 63/4885MAT2A 1005/4885KCNH2 4735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.